Michael P. Lux
YOU?
Author Swipe
View article: Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial Open
Neoadjuvant T-DXd-THP demonstrated statistically significant and clinically meaningful pCR benefit and improved safety versus ddAC-THP.
View article: Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer
Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer Open
Although the choice of chemotherapy post-CDK4/6i did not significantly affect PFS or OS, combinations with bevacizumab may have some benefit. Nevertheless, considering side effects may be most important when choosing the type of second-lin…
View article: Evaluating a Chatbot as a Companion for Patients With Breast Cancer: Collaborative Pilot Study
Evaluating a Chatbot as a Companion for Patients With Breast Cancer: Collaborative Pilot Study Open
Background Patients with breast cancer frequently experience significant uncertainty, prompting them to seek detailed, personalized, and reliable medical information to enhance adherence to prescribed treatments, medications, and recommend…
View article: Palbociclib: randomisierte Studien und Real-World-Evidenz als Grundlage für die Therapieplanung beim metastasierten Mammakarzinom
Palbociclib: randomisierte Studien und Real-World-Evidenz als Grundlage für die Therapieplanung beim metastasierten Mammakarzinom Open
Zusammenfassung Die endokrin basierte Kombinationstherapie mit einem Inhibitor der cyclinabhängigen Kinasen 4 und 6 (CDK4/6-Inhibitor) gilt heute als Erstlinientherapie der ersten Wahl für Patientinnen und Patienten mit hormonrezeptorposit…
View article: Re-Operation Rate for Breast Conserving Surgery Using Confocal Histolog Scanner for Intraoperative Margin Assessment—SHIELD Study
Re-Operation Rate for Breast Conserving Surgery Using Confocal Histolog Scanner for Intraoperative Margin Assessment—SHIELD Study Open
Introduction: In breast conserving surgery (BCS), 15–40% of patients must undergo a second surgery (re-operation) due to post-surgical cancer-positive margins. Efficient intraoperative assessment of lumpectomy margins can reduce this rate.…
View article: Update Breast Cancer 2024 Part 3 – Patients with Advanced Stage Breast Cancer
Update Breast Cancer 2024 Part 3 – Patients with Advanced Stage Breast Cancer Open
The use of CDK4/6 inhibitors, the new PI3K/AKT-kinase inhibitors, selective estrogen receptor-degraders (SERDs), antibody-drug conjugates, immune therapies and PARP inhibitors in recent years has resulted in a marked change in the therapy …
View article: Update Breast Cancer 2024 Part 2 – Patients with Early Stage Breast Cancer
Update Breast Cancer 2024 Part 2 – Patients with Early Stage Breast Cancer Open
This review summarizes the latest developments for the treatment of patients with early-stage breast cancer. Most of the clinically relevant changes were the result of using immune checkpoint inhibitors to treat patients with triple-negati…
View article: Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancer
Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancer Open
HRpos/HER2neg first-line MBC patients have a more favorable prognosis if the disease was previously not treated. This difference was similar across all examined clinicopathological parameters. It may therefore be beneficial to incorporate …
View article: Update Mammakarzinom 2024 Teil 1 – Expertenmeinungen zu Brustkrebs in fortgeschrittenen Krankheitsstadien
Update Mammakarzinom 2024 Teil 1 – Expertenmeinungen zu Brustkrebs in fortgeschrittenen Krankheitsstadien Open
Klinische Evidenz wird auf Basis klinischer Studien und der persönlichen Erfahrung interpretiert. Dies kann in einer unterschiedlichen Deutung der Datenlage resultieren. Vor diesem Hintergrund sind Expertenpanels wie das Advanced Breast Ca…
View article: The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype
The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype Open
View article: Topical treatment of chemotherapy-induced peripheral neuropathy (CIPN) with high-concentration (179 mg) capsaicin patch in breast cancer patients – results of the QUCIP study
Topical treatment of chemotherapy-induced peripheral neuropathy (CIPN) with high-concentration (179 mg) capsaicin patch in breast cancer patients – results of the QUCIP study Open
Background Chemotherapy-induced peripheral neuropathy (CIPN) following oral or intravenous chemotherapy often results in neuropathic pain, accompanied by symptoms such tingling, burning and hypersensitivity to stimuli, with a notable decli…
View article: Palbociclib: Randomized Studies and Real-world Evidence as the Basis for Therapeutic Planning in Metastatic Breast Cancer
Palbociclib: Randomized Studies and Real-world Evidence as the Basis for Therapeutic Planning in Metastatic Breast Cancer Open
Endocrine-based combination therapy with an inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6 inhibitors) is currently the first-line therapy of choice for patients with hormone receptor-positive (HR+) and human epidermal growth fa…
View article: Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer Open
View article: Update Breast Cancer 2024 Part 1 – Expert Opinion on Advanced Breast Cancer
Update Breast Cancer 2024 Part 1 – Expert Opinion on Advanced Breast Cancer Open
Clinical evidence is interpreted based on clinical studies and personal experience which can lead to different interpretations of data. This makes the opinions issued by panels of experts such as the Advanced Breast Cancer Panel which conv…
View article: 209P Real-world effectiveness of palbociclib + endocrine therapy in HR+/HER2- advanced breast cancer patients: Interim results of the PERFORM study
209P Real-world effectiveness of palbociclib + endocrine therapy in HR+/HER2- advanced breast cancer patients: Interim results of the PERFORM study Open
Endocrine therapy (ET) + CDK4/6 inhibitors are first-line (1L) standard in patients (pts) with HR+/HER2- advanced breast cancer (ABC). High efficacy and good tolerability have been shown in randomized clinical trials. To support these find…
View article: CDK4/6 Inhibition – Therapy Sequences and the Quest to Find the Best Biomarkers – an Overview of Current Programs
CDK4/6 Inhibition – Therapy Sequences and the Quest to Find the Best Biomarkers – an Overview of Current Programs Open
In recent years, new targeted therapies have been developed to treat patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer. Some of these therapies have not just become the ne…
View article: Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT Registry
Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT Registry Open
Background With more effective therapies for patients with advanced breast cancer (aBC), therapy sequences are becoming increasingly important. However, some patients might drop out of the treatment sequence due to deterioration of their l…
View article: App-based support for breast cancer patients to reduce psychological distress during therapy and survivorship – a multicentric randomized controlled trial
App-based support for breast cancer patients to reduce psychological distress during therapy and survivorship – a multicentric randomized controlled trial Open
Introduction The negative impact of unmanaged psychological distress on quality of life and outcome in breast cancer survivors has been demonstrated. Fortunately, studies indicate that distress can effectively be addressed and even prevent…
View article: Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study
Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study Open
PURPOSE To compare giredestrant and physician's choice of endocrine monotherapy (PCET) for estrogen receptor–positive, HER2-negative, advanced breast cancer (BC) in the phase II acelERA BC study (ClinicalTrials.gov identifier: NCT04576455 …
View article: Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024
Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024 Open
The Breast Committee of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO) presents the 2024 update of the evidence-based recommendations for the diagnosis and treatment of patients with locally adv…
View article: Biochemical and Genetic Testing of GAA in Over 30.000 Symptomatic Patients Suspected to Be Affected With Pompe Disease
Biochemical and Genetic Testing of GAA in Over 30.000 Symptomatic Patients Suspected to Be Affected With Pompe Disease Open
Pompe disease (PD) is a rare autosomal recessive lysosomal disorder caused by loss‐of‐function of the α ‐glucosidase ( GAA ) gene. The deficient GAA enzyme activity may result in potential life‐threatening muscle weakness, thus requiring a…
View article: Budget Impact of the Oncotype DX Breast Recurrence Score<sup>®</sup> Test in Patients with Early Primary Hormone-Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in Germany
Budget Impact of the Oncotype DX Breast Recurrence Score<sup>®</sup> Test in Patients with Early Primary Hormone-Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in Germany Open
Background: Gene expression tests can inform decisions on whether to recommend or omit chemotherapy for patients with early HR+, HER2− breast cancer. The benefit of these tests is well established and fully reimbursed by sick…
View article: Update Mammakarzinom 2023 Teil 3 – Expertenmeinungen zu Brustkrebs in frühen Krankheitsstadien
Update Mammakarzinom 2023 Teil 3 – Expertenmeinungen zu Brustkrebs in frühen Krankheitsstadien Open
Zusammenfassung In einem 2-jährigen Rhythmus fand in St. Gallen in früheren Jahren und nun in Wien die „St. Gallen (SG) International Breast Cancer Conference“ statt. Dieses Jahr (2023) wurde diese Konferenz, die sich mit der Behandlung vo…
View article: Das Mammakarzinom und die genetische BRCA1/2-Testung in der klinischen Routine: warum, wann und für wen?
Das Mammakarzinom und die genetische BRCA1/2-Testung in der klinischen Routine: warum, wann und für wen? Open
Zusammenfassung Pathogene Varianten der Tumorsuppressorgene BRCA1 und BRCA2 sind für den Großteil der hereditären Mammakarzinome verantwortlich und gewinnen zunehmend an Bedeutung für die Bestimmung der Eignung einer zielgerichteten Therap…
View article: Update Mammakarzinom 2023 Teil 2 – Brustkrebs in fortgeschrittenen Krankheitsstadien
Update Mammakarzinom 2023 Teil 2 – Brustkrebs in fortgeschrittenen Krankheitsstadien Open
Zusammenfassung Eine Reihe von neuen Therapien hat in den letzten Jahren die Fortschritte in der Behandlung von Patientinnen mit fortgeschrittenem Mammakarzinom bestimmt. Diese Substanzen sind hauptsächlich die CDK4/6-Inhibitoren und weite…
View article: 317P Awareness of genomic testing among patients with breast cancer in Europe
317P Awareness of genomic testing among patients with breast cancer in Europe Open
View article: 407P Palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer patients: Interim results of the PERFORM study
407P Palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer patients: Interim results of the PERFORM study Open
View article: Update Breast Cancer 2023 Part 3 – Expert Opinions of Early Stage Breast Cancer Therapies
Update Breast Cancer 2023 Part 3 – Expert Opinions of Early Stage Breast Cancer Therapies Open
The St. Gallen (SG) International Breast Cancer Conference is held every two years, previously in St. Gallen and now in Vienna. This year (2023) marks the eighteenth edition of this conference, which focuses on the treatment of patients wi…
View article: Association of the <scp> <i>CHEK2</i> </scp> c. <scp>1100delC</scp> variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer‐specific survival
Association of the <span> <i>CHEK2</i> </span> c. <span>1100delC</span> variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer‐specific survival Open
Background Breast cancer (BC) patients with a germline CHEK2 c.1100delC variant have an increased risk of contralateral BC (CBC) and worse BC‐specific survival (BCSS) compared to non‐carriers. Aim To assessed the associations of CHEK2 c.11…
View article: Update Breast Cancer 2023 Part 1 – Early Stage Breast Cancer
Update Breast Cancer 2023 Part 1 – Early Stage Breast Cancer Open
With abemaciclib (monarchE study) and olaparib (OlympiA study) gaining approval in the adjuvant treatment setting, a significant change in the standard of care for patients with early stage breast cancer has been established for some time …